目的 探讨炎性乳腺癌的临床特点和治疗方法。 方法 对我院1989年2月至1997年11月期间诊治的17例炎性乳腺癌患者的临床资料进行回顾性分析。 结果 17例患者中8例行新辅助化疗+乳腺癌改良根治术+术后放疗及化疗患者的平均生存期为33.6个月，1、2、5年仍存活者分别为6例、5例和3例，行其他治疗的9例患者1、2、5年仍存活者分别为5例、3例和0例。 结论 新辅助化疗+乳腺癌改良根治术+术后放疗及化疗可提高患者生存率。
Objective To explore the effects of overexpression of human tissue inhibitors of metalloproteinase-1 (hTIMP-1) on proliferation of human liver cancer cell line HepG2 in vitro. Methods A recombinant adenoviral vector containing full-length cDNA of hTIMP-1 was generated and transfected into HepG2. The viral titer was checked by measuring GFP, and the expression of hTIMP-1 in vitro was detected by the techniques of Western blot and semi-quantitative RT-PCR. The ultrastructure was observed by transmission electron microscope and the effects of overexpression of hTIMP-1 on proliferation of HepG2 in vitro was analyzed by MTT assay and growth curve. Results The resultant AdhTIMP-1 was successfully constructed and the expression of hTIMP-1 was detected by Western blot and RT-PCR. The growth and proliferation of HepG2, which had been transfected with AdhTIMP-1, was significantly inhibited. Conclusion The proliferation of HepG2 was markedly inhibited by recombinant adenovirus-mediated overexpression of hTIMP-1, which may pave the way for further application in liver gene therapy.